Discover investment opportunities in Top 20 Stocks Under $1 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top 20 Stocks Under $1 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top 20 Stocks Under $1 using our Smart AI Filter.
8 stocks found for "Top 20 Stocks Under $1"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.76 Risk measure | ±100.0% Price volatility | -0.1 Valuation | 0.00% Annual yield | |||
1.24 Risk measure | ±72.2% Price volatility | -6.2 Valuation | 0.00% Annual yield | |||
0.64 Risk measure | ±100.0% Price volatility | -0.4 Valuation | 0.00% Annual yield | |||
0.15 Risk measure | ±100.0% Price volatility | -0.2 Valuation | 0.00% Annual yield | |||
1.56 Risk measure | ±83.0% Price volatility | -16.0 Valuation | 0.00% Annual yield | |||
0.65 Risk measure | ±93.4% Price volatility | -1.0 Valuation | 0.00% Annual yield | |||
1.11 Risk measure | ±100.0% Price volatility | — Valuation | 0.00% Annual yield | |||
1.01 Risk measure | ±72.3% Price volatility | -3.1 Valuation | 0.00% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What potential growth opportunities exist for KXIN given its current price of under $1?
A: KXIN operates in the electric vehicle sector, which is experiencing rapid growth globally. Despite its low price, some investors see potential in its innovative approach and partnerships within the EV market. However, risks include high competition and regulatory challenges in both domestic and international markets.
Q: How does VTAK's performance influence its appeal for speculative investors?
A: VTAK is associated with biotechnology, a sector known for significant volatility and potential high rewards. This could attract speculative investors looking for quick gains, though the industry's dependency on successful clinical results adds considerable risk.
Q: Does NUWE offer any competitive advantage within its industry at under $1?
A: NUWE engages in healthcare-related operations, often prioritizing innovative solutions. Its low stock price might intrigue investors interested in emerging medical technologies, but the competitive nature of the industry and challenges in development stages pose risks.
Q: What factors should be considered when assessing VXRT for potential substantial gains?
A: VXRT focuses on oral vaccines, which provides a unique position in the biotech industry. Investors may consider the potential wide applications and ease of distribution. However, reliance on clinical trial outcomes and regulatory approvals are critical factors.
Q: In what ways might ONCY's focus on cancer treatment drugs affect its stock potential?
A: ONCY's research in oncology drugs targets a high-demand market. Its progress in clinical trials could influence stock valuation positively. Nonetheless, competition and the lengthy approval process in the pharmaceutical industry remain significant challenges.
Q: What are HCTI's sector-specific risks at its current price level?
A: HCTI is involved in the construction sector, where economic cycles significantly impact performance. Risks include fluctuating demand, regulatory compliance costs, and competition from larger, established firms.
Discover why Zacks rates Healthcare Triangle as "Underperform", being the first on Wall Street to initiate coverage on the stock. Explore HCTI's heavy reliance on top clients amid liquidity issues and ongoing losses.
Read more